Ibrutinib

ATC L01EL01 · 11 markets · 47 records

Ibrutinib 11 markets · 47 records Forms

AU 11 records · 6 strengths

  • 140 mgcapsuleImbruvicaIMBRUVICA ibrutinib 140 mg capsule bottle also in US·CA·GB +3 unknown
  • 140 mgtabletIMBRUVICA ibrutinib 140 mg film-coated tablet blister also in US·CA·GB +4 unknown
  • 280 mgtabletImbruvicaIMBRUVICA ibrutinib 140 mg film-coated tablet blister also in US·CA·GB +2 unknown
  • 420 mgtabletImbruvicaIMBRUVICA ibrutinib 140 mg film-coated tablet blister also in US·CA·GB +1 unknown
  • 560 mgtabletImbruvicaIMBRUVICA ibrutinib 140 mg film-coated tablet blister also in CA·GB·ES unknown

Records without a stated strength · 1 Imbruvica

US 6 records · 6 strengths

CA 6 records · 6 strengths

GB 5 records · 5 strengths

ES 5 records · 5 strengths

TW 4 records · 3 strengths

HK 3 records · 1 strengths

    Records without a stated strength · 1 Imbruvica

    CN 2 records · 1 strengths

    SG 1 records · 1 strengths

    MX 1 records · 1 strengths

    EU 1 records · 1 strengths

    EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

      Records without a stated strength · 1 Imbruvica

      Side-by-side table

      The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

      Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.